Masterhead

Thank you for visiting south-san-francisco.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Compugen Announces Presentations of COM701 Immuno-oncology Pipeline Product and Predictive Discovery Methodology for Novel Immune Checkpoints at AACR

Published Thursday March 2

HOLON, Israel Thu Mar 2 /PRNewswire/ — Compugen Limited , a leading therapeutic discovery company, announced today that 2 abstracts

Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG Abstract 581, Sun April 2 1:00 – 5:00 pm ET

Compugen is a leading therapeutic discovery company whose mission is to utilize its broadly applicable predictive discovery infrastructure to discover

In addition, our pipeline currently includes a preclinical stage fusion protein autoimmune product candidate. Compugen’s business model is based on sel

Article length: About 710 words.
Tags: South San Francisco
Read more at Medindia

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b